Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999

Clinical Infectious Diseases

Volumn 32, Issue 10 SUPPL. 2, 2001, Pages

  Gales, A C ^a   Jones, R N ^a   Turnidge, J ^a   Rennie, R ^a   Ramphal, R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CANADA; CENTRAL AMERICA; CLONE; CONFERENCE PAPER; EUROPE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RIBOTYPING; SOUTH AMERICA;

EID: 0035873752     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/320186     Document Type: Conference Paper

References (77)

1. Pseudomonas
2. Pseudomonas aeruginosa
3. Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: Risk factors and outcome
4. Adherence of Pseudomonas aeruginosa to tracheal cells injured by influenza infection or by endotracheal intubation
5. TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient
6. Beta-lactamase-mediated resistance to extended spectrum cephalosporins among clinical isolates of Pseudomonas aeruginosa
7. Control of outbreaks due to organisms producing extended-spectrum β-lactamases
8. Extended-spectrum β-lactamases in Pseudomonas aeruginosa
9. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems
10. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-β-lactamase gene blaIMP
11. Acquired carbapenemases
12. Carbapenem-hydrolyzing metallo-β-lactamases in Pseudomonas aeruginosa
13. Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain
14. National Nosocomial Infections Surveillance (NNIS) system report: Data summary from October 1986-April 1998, issued June 1998
15. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) surveillance report: Data summary from January 1996 through December 1997. A report from the National Nosocomial Infections Surveillance (NNIS) system
16. United States geographic bacteria susceptibility patterns
17. Epidemiological study of variations in β-lactam antibiotic susceptibility of Pseudomonas aeruginosa in two intensive care units
18. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa
19. Further occurrence of extended-spectrum β-lactamase-producing Salmonella enteritidis
20. Mechanisms of β-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey
21. Lack of additive effect between mechanisms of resistance to carbapenems and other β-lactam agents in Pseudomonas aeruginosa
22. Interplay between chromosomal β-lactamase and the MexAB-OprM efflux system in intrinsic resistance to β-lactams in Pseudomonas aeruginosa
23. Resistance of Pseudomonas aeruginosa to imipenem induced by eluates from siliconized latex urinary catheters is related to outer membrane protein alterations
24. A study of the mechanisms involved in imipenem resistance in Pseudomonas aeruginosa isolates from Japan
25. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa
26. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to amino-glycosides
27. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa
28. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones
29. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents
30. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii
31. A TEM-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa
32. Epidemiologic typing of multiple drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit
33. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: The results of an Italian multicenter study
34. Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11
35. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability
36. Carbapenemase-producing Pseudomonas aeruginosa in UK
37. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations
38. Bacterial resistance: A worldwide problem
39. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM
40. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria
41. Carbapenem activities against Pseudomonas aeruginosa: Respective contributions of OprD and efflux systems
42. Worldwide proliferation of carbapenem-resistant gram-negative bacteria
43. Epidemiology and clinical outcomes of patients with multi-resistant Pseudomonas aeruginosa
44. Canadian Pseudomonas aeruginosa susceptibility, study from 48 medical centers: Focus on ciprofloxacin
45. Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic
46. Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis unit
47. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens
48. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis
49. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries
50. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria
51. Quality of antimicrobial susceptibility testing in the UK: A Pseudomonas aeruginosa survey revisited
52. Comparative evaluation of an automated ribotyping system versus pulsed-field gel electrophoresis for epidemiological typing of clinical isolates of Escherichia coli and Pseudomonas aeruginosa from patients with recurrent gram-negative bacteremia
53. Nosocomial infections in medical intensive care units in the United States
54. Surveillance of Pseudomonas aeruginosa in intensive care units: Clusters of nosocomial cross-infection and encounter of a multiple-antibiotic resistant strain
55. The prevalence of nosocomial infection in intensive care units in Europe
56. OXA-16, a further extended-spectrum variant of OXA-10 β-lactamase, from two Pseudomonas aeruginosa isolates
57. Laboratory mutants of OXA-10 β-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa
58. Resistance to β-lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and β-lactamase
59. Antibiotic resistance caused by gram-negative multidrug efflux pumps
60. Carbapenem-hydrolyzing β-lactamases
61. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: A nationwide multicenter study
62. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa
63. Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns
64. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa
65. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals
66. Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against over 2000 clinical isolates from 22 medical centers in Japan
67. Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain
68. In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa
69. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa
70. An 8 year Microbe Base survey of the epidemiology, frequency and antibiotic susceptibility of Pseudomonas aeruginosa hospital isolates in the United Kingdom
71. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobiai susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
72. Multiresistant Pseudomonas aeruginosa outbreak in a pediatric oncology ward related to bath toys
73. Carbapenem-hydrolysing β-lactamase from clinical isolates of Pseudomonas aeruginosa in Portugal
74. Management of fluoroquinolone resistance in Pseudomonas aeruginosa - Outcome of monitored use in a referral hospital
75. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa
76. Quorum sensing: Potential means of treating gram-negative infections?